Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0GX3L
|
|||
| Former ID |
DNCL003540
|
|||
| Drug Name |
Arbaclofen placarbil
|
|||
| Synonyms |
AP; R-baclofen - XenoPort; XP-19986
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Fragile X syndrome [ICD-11: LD55; ICD-10: Q99.2] | Phase 3 | [1] | |
| Alcohol dependence [ICD-11: 6C40.2; ICD-10: F10.2; ICD-9: 303] | Phase 2 | [2] | ||
| Company |
Genentech
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H26ClNO6
|
|||
| Canonical SMILES |
CC(C)C(OC(=O)C(C)C)OC(=O)NCC(CC(=O)O)C1=CC=C(C=C1)Cl
|
|||
| InChI |
1S/C19H26ClNO6/c1-11(2)17(24)26-18(12(3)4)27-19(25)21-10-14(9-16(22)23)13-5-7-15(20)8-6-13/h5-8,11-12,14,18H,9-10H2,1-4H3,(H,21,25)(H,22,23)/t14-,18-/m0/s1
|
|||
| InChIKey |
JXTAALBWJQJLGN-KSSFIOAISA-N
|
|||
| CAS Number |
CAS 847353-30-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
3153571, 8178796, 11113710, 15121255, 15171983, 34709846, 50066102, 50705527, 90452213, 93625490, 103238751, 103941336, 104345301, 121277848, 123055284, 124490531, 124580859, 126581462, 126616647, 126685003, 126738367, 128418031, 134351756, 135249532, 135649977, 139309014, 143493644, 152032454, 152165673, 152238531, 152258754, 160647599, 160840514, 162009782, 162255234, 163099671, 163405182, 166222624, 170475242, 170485722, 172914818, 175266631, 175270364, 178100431, 186007019, 198993730, 204431203, 208265328, 223518884, 223679055
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | GABA(A) receptor gamma-3 (GABRG3) | Target Info | Agonist | [2] |
| Gamma-aminobutyric acid B receptor (GABBR) | Target Info | Modulator | [3] | |
| KEGG Pathway | cAMP signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| GABAergic synapse | ||||
| Estrogen signaling pathway | ||||
| Morphine addiction | ||||
| Retrograde endocannabinoid signaling | ||||
| Nicotine addiction | ||||
| Reactome | Activation of G protein gated Potassium channels | |||
| G alpha (i) signalling events | ||||
| Class C/3 (Metabotropic glutamate/pheromone receptors) | ||||
| Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | ||||
| Ligand-gated ion channel transport | ||||
| GABA A receptor activation | ||||
| WikiPathways | GPCRs, Class C Metabotropic glutamate, pheromone | |||
| Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell | ||||
| Potassium Channels | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| SIDS Susceptibility Pathways | ||||
| Iron uptake and transport | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01325220) Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Arbaclofen placarbil, a novel R-baclofen prodrug: improved absorption, distribution, metabolism, and elimination properties compared with R-baclofen.J Pharmacol Exp Ther.2009 Sep;330(3):911-21. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.